Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Next Previous
Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OS440-3005
  • Sponsors RVL Pharmaceuticals

Most Recent Events

  • 21 Apr 2022 Status changed from active, no longer recruiting to completed.
  • 30 Mar 2021 According to an Osmotica Pharmaceutical media release, the company had constructive Type A meeting with the FDA and the company is exploring a number of options define a path forward, which will most likely include another clinical trial.
  • 29 Dec 2020 According to an Osmotica Pharmaceutical media release, the company intends to review the CRL with its advisors and to request a meeting with the FDA to discuss their recommendations.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top